InvestorRoom | Kitov Pharmaceuticals http://kitovpharma.investorroom.com/ Kitov Boosts Ownership in TyrNovo and Oncology Platform Through Exchange of Shares for Stock http://kitovpharma.investorroom.com/2017-10-06-Kitov-Boosts-Ownership-in-TyrNovo-and-Oncology-Platform-Through-Exchange-of-Shares-for-Stock - Kitov acquires an additional 27% ownership stake in TyrNovo and NT219, its oncology therapeutic candidate, in exchange for Kitov stock at a value of $2.50 per ADS. Fri, 06 Oct 2017 08:20:00 -0400 http://kitovpharma.investorroom.com/2017-10-06-Kitov-Boosts-Ownership-in-TyrNovo-and-Oncology-Platform-Through-Exchange-of-Shares-for-Stock Kitov Announces Filing by FDA of New Drug Application for KIT-302 http://kitovpharma.investorroom.com/news-releases?item=55 Mon, 02 Oct 2017 06:36:00 -0400 http://kitovpharma.investorroom.com/news-releases?item=55 Kitov Pharmaceuticals Provides Corporate Update and Reports First Half 2017 Financial Results http://kitovpharma.investorroom.com/2017-08-16-Kitov-Pharmaceuticals-Provides-Corporate-Update-and-Reports-First-Half-2017-Financial-Results Wed, 16 Aug 2017 16:35:00 -0400 http://kitovpharma.investorroom.com/2017-08-16-Kitov-Pharmaceuticals-Provides-Corporate-Update-and-Reports-First-Half-2017-Financial-Results Kitov Submits New Drug Application to FDA for KIT-302 http://kitovpharma.investorroom.com/news-releases?item=53 Mon, 31 Jul 2017 15:29:00 -0400 http://kitovpharma.investorroom.com/news-releases?item=53 Kitov Announces Results of Study Demonstrating NT-219 Enhanced Efficacy of Keytruda® in Immune-Oncology Preclinical Model http://kitovpharma.investorroom.com/2017-07-18-Kitov-Announces-Results-of-Study-Demonstrating-NT-219-Enhanced-Efficacy-of-Keytruda-R-in-Immune-Oncology-Preclinical-Model Tue, 18 Jul 2017 08:36:00 -0400 http://kitovpharma.investorroom.com/2017-07-18-Kitov-Announces-Results-of-Study-Demonstrating-NT-219-Enhanced-Efficacy-of-Keytruda-R-in-Immune-Oncology-Preclinical-Model